Abstract
Cefazolin, a new derivative of 7-ACA, has been evaluated at our laboratory on clinical isolates and clinically on urinary tract infections. Cefazolin has bactericidal effect on most E. coli strains. It is also active against some other coliform bacilli an i some Proteus strains even when they are highly resistant to all synthetic penicillins due to penicillinase production. However, most indole positive Proteus and Pseudomonas species are resistant to this drug as in the cases of other cephalosporin C antibiotics. Clinically, Cefazolin has been proved effective in more than 90% of acute urinary tract infections due to E. coli strains. However, in many complicated urinary tract infections, superinfection due to resistant Pseudomonas and Proteus strains has made Cefazolin treatment ineffective. No severe untoward effect has been found except for mild to moderate pain at the injection site.
